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Daptomycin-nonsusceptible (DNS) Staphylococcus aureus strains have been reported over the last several years. Telavancin is a
lipoglycopeptide with a dual mechanism of action, as it inhibits peptidoglycan polymerization/cross-linking and disrupts the
membrane potential. Three clinical DNS S. aureus strains, CB1814, R6212, and SA-684, were evaluated in an in vitro pharmaco-
kinetic/pharmacodynamic (PK/PD) model with simulated endocardial vegetations (starting inoculum, 108.5 CFU/g) for 120 h.
Simulated regimens included telavancin at 10 mg/kg every 24 h (q24h; peak, 87.5 mg/liter; t1/2, 7.5 h), daptomycin at 6 mg/kg
q24h (peak, 95.7 mg/liter; t1/2, 8 h), and vancomycin at 1 g q12h (peak, 30 mg/liter; t1/2, 6 h). Differences in CFU/g between regi-
mens at 24 through 120 h were evaluated by analysis of variance with a Tukey’s post hoc test. Bactericidal activity was defined as
a >3-log10 CFU/g decrease in colony count from the initial inoculum. MIC values were 1, 0.25, and 0.5 mg/liter (telavancin), 4, 2,
and 2 mg/liter (daptomycin), and 2, 2, and 2 mg/liter (vancomycin) for CB1814, R6212, and SA-684, respectively. Telavancin dis-
played bactericidal activities against R6212 (32 to 120 h; 4.31 log10 CFU/g), SA-684 (56 to 120 h; 3.06 log10 CFU/g), and
CB1814 (48 to 120 h; 4.9 log10 CFU/g). Daptomycin displayed initial bactericidal activity followed by regrowth with all three
strains. Vancomycin did not exhibit sustained bactericidal activity against any strain. At 120 h, telavancin was significantly bet-
ter at reducing colony counts than vancomycin against all three tested strains and better than daptomycin against CB1814 (P <
0.05). Telavancin displayed bactericidal activity in vitro against DNS S. aureus isolates.
There are limited treatment options for multidrug-resistantGram-positive pathogens, including daptomycin-nonsuscep-
tible (DNS) Staphylococcus aureus. Currently, DNS S. aureus iso-
lates are defined by the Clinical and Laboratory Standards Insti-
tute (CLSI) as organisms with a daptomycin MIC of 1 mg/liter
(7). Although relatively rare (0.01 to 0.1%), DNS S. aureus pres-
ents a unique treatment challenge to clinicians when encountered,
as it often occurs in high-inoculum infections requiring pro-
longed therapy, such as endocarditis, osteomyelitis, septic joint
infections, and complicated bacteremia (4, 13, 21, 30). The opti-
mal therapy for infections with DNS S. aureus remains undefined.
Potential treatment options for DNS S. aureus infections cited in
the recent guidelines from the Infectious Diseases Society of
America on the treatment of methicillin-resistant S. aureus
(MRSA) infections are based on limited data and include
quinupristin-dalfopristin, trimethoprim-sulfamethoxazole, dap-
tomycin plus trimethoprim-sulfamethoxazole, linezolid, and tela-
vancin (21).
Telavancin is a new lipoglycopeptide with activity against
Gram-positive organisms, including S. aureus. Telavancin acts
through a dual mechanism that includes inhibition of phosphati-
dylglycerol synthesis and disruption of bacterial membrane bar-
rier function (22, 23). It is hypothesized that this dual mechanism
accounts for the increased potency and low MIC90 values of 0.25
mg/liter against S. aureus (27, 28). This dual mechanism of action
may therefore afford telavancin an advantage in treating drug-
resistant Gram-positive organisms, including DNS S. aureus. In
the current investigation, we evaluated telavancin versus dapto-
mycin and vancomycin against DNS S. aureus isolates in an in vitro
pharmacokinetic/pharmacodynamic (PK/PD) model of simu-
lated endocardial vegetations.
(This study was presented as a poster presentation at the 51st
Interscience Conference on Antimicrobial Agents and Chemo-
therapy (ICAAC), Chicago, IL, 2011.)
MATERIALS AND METHODS
Bacterial strains. A total of three clinical DNS S. aureus isolates were
evaluated: SA-684 (a MRSA strain recovered from a patient during ther-
apy for tricuspid endocarditis; provided by G. W. Kaatz, J. Dingell VA
Hospital, Detroit, MI); CB1814 (a methicillin-susceptible S. aureus isolate
from the daptomycin bacteremia and endocarditis clinical trial); R6212 (a
heteroresistant vancomycin-intermediate S. aureus [hVISA] isolate from
Detroit Medical Center) (17). In all isolates, the DNS was stable to 5 serial
passages on tryptic soy agar and was confirmed by daptomycin population
analysis (data not shown).
Antimicrobials. Telavancin (Theravance, Inc., South San Francisco,
CA) was provided by the manufacturer. Daptomycin was commercially
purchased (Cubist Pharmaceuticals). Vancomycin was obtained from
Sigma Chemical Company (St. Louis, MO).
Media. Mueller-Hinton broth II (Difco, Detroit, MI) with 25 mg/liter
calcium and 12.5 mg/liter magnesium (MHB II) was used for all in vitro
PK/PD models used to evaluate telavancin and vancomycin. Supple-
mented Mueller-Hinton broth (SMHB) supplemented to 75 mg/liter cal-
cium (equivalent to 50 mg/liter of calcium in the presence of albumin) was
used for all in vitro PK/PD models due to the dependency of daptomycin
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on calcium for antimicrobial activity (1, 19). MHB II and agar (Bacto;
Difco, Detroit, MI) supplemented with 50 mg/liter of calcium were used
for population analysis and daptomycin drug plates. Brain heart infusion
agar (Difco, Detroit, MI) was used for vancomycin drug plates. Colony
counts were determined using tryptic soy agar (TSA; Difco, Detroit, MI)
plates.
Susceptibility testing. MICs were determined by broth microdilution
to 106 according to the Clinical and Laboratory Standards Institute guide-
lines (7). All samples were incubated at 35°C for 24 h.
SEVs. Simulated endocardial vegetations (SEVs) were prepared as
previously described (1, 5, 6, 15, 20, 29, 32–34). Organism stocks were
prepared by inoculating three TSA plates with lawns for overnight growth
at 35°C. Organisms were swabbed from the growth plates into 5-ml test
tubes of SMHB, resulting in a concentration of approximately 1010 CFU/
ml. SEVs were prepared in 1.5-ml siliconized Eppendorf tubes by mixing
0.05 ml of diluted organism suspension (final inoculum, 8.5 log10 CFU/
0.5 g), 0.5 ml of cryoprecipitated human antihemophilic factor from vol-
unteer donors (American Red Cross, Detroit, MI), and 0.025 ml of platelet
suspension (platelets mixed with normal saline; 250,000 to 500,000 plate-
lets per clot). A volume of 0.05 ml of bovine thrombin (5,000 units/ml;
GenTrac, Inc., Middleton, WI) was added to each tube after insertion of a
sterile monofilament line into the mixture. The resultant simulated vege-
tations were then removed from the Eppendorf tubes by using a sterile
disposable plastic needle (Becton Dickinson, Sparks, MD) and introduced
into the model. This methodology resulted in each SEV consisting of
approximately 3 to 3.5 g/dl of albumin and 6.8 to 7.4 g/dl of total protein.
In vitro PK/PD model. A two-compartment in vitro model consisting
of a 250-ml two-compartment glass apparatus with ports, in which the
SEVs were suspended, was utilized for all simulations (1, 5, 6, 15, 20, 29,
32–34). The apparatus was prefilled with medium, and antibiotics were
administered as boluses over a 120-h time period into the central com-
partment via an injection port. The model apparatus was placed in a 37°C
water bath throughout the procedure, and a magnetic stir bar was placed
in the medium for thorough mixing of the drug in the model. Fresh
medium was continuously supplied and removed from the compartment
along with the drug via a peristaltic pump (Masterflex; Cole-Parmer In-
strument Company, Chicago, IL) set to simulate the half-lives of the an-
tibiotics. Simulated antibiotic regimens included telavancin at 10 mg/kg
every 24 h (peak, 87.5 mg/liter; average half-life, 7.5 h), daptomycin at 6
mg/kg every 24 h (peak, 95.7 mg/liter; average half-life, 8 h), and vanco-
mycin at 1 g every 12 h (peak, 30 mg/liter; average half-life, 6 h) (3, 31). All
models were evaluated in duplicate.
Pharmacodynamic analysis. Two simulated endocardial vegetations
were removed from the SEV model at 0, 4, 8, 24, 32, 48, 56, 72, 96, and 120
h (1, 5, 6, 15, 20, 29, 32–34). The SEVs were homogenized and diluted in
cold saline to be plated onto TSA plates. If the vancomycin or daptomycin
concentration at the anticipated dilution was within 1 tube dilution of the
MIC or higher, then vacuum filtration was used to avoid antibiotic carry-
over. When vacuum filtration was used, samples were washed through a
0.45-m filter with normal saline to remove the antimicrobial agent and
recover the bacteria on the filter, which was then placed on a TSA plate.
These methods have a lower limit of reliable detection of 1 log10 CFU/g.
Telavancin carryover cannot be handled by this method, likely due to
binding to the filter paper. If the telavancin concentration at the antici-
pated dilution was within 1 tube dilution of the MIC or higher, the sam-
ples were pelleted by centrifugation and the supernatant removed before
being resuspended in 0.5 ml of normal saline. These samples were pro-
cessed through a 5-m filter needle twice (to bind telavancin) before the
samples were drop plated as usual. This method has a lower limit of reli-
able detection of 3.5 log10 CFU/g. Plates were incubated at 35°C for 24 h,
at which time colony counts were performed. The total reduction in the
log10 CFU/g over 120 h was determined by plotting time-kill curves based
on the number of remaining organisms over the 120-h time period. Bac-
tericidal activity (99.9% kill) was defined as a 3-log10 CFU/g reduction
in colony count from the initial inoculum. Bacteriostatic activity was de-
fined as a 3-log10 CFU/g reduction in colony count from the initial
inoculum, while inactivity was defined as no observed reductions in initial
inocula. The time to achieve 99.9% bacterial load reduction was deter-
mined by linear regression or visual inspection (if r2 was 0.95).
Pharmacokinetic analysis. Pharmacokinetic samples were obtained
through the injection port of each model (in duplicate) at 0.5, 1, 2, 4, 8, 24,
32, 48, 56, 72, 96, and 120 h for verification of target antibiotic concentra-
tions. All samples were stored at 70°C until analysis. Vancomycin con-
centrations were determined in a fluorescence polarization immunoassay
(Abbott Diagnostics TDx). This assay has a limit of detection of 2.0 g/ml
with a coefficient variation (CV) of 12%. Concentrations of telavancin
and daptomycin were determined by microbioassay by utilizing Micrococ-
cus luteus ATCC 9341. For telavancin, holes were made in antibiotic me-
dium 11 agar plates (Difco, Detroit, MI) preswabbed with a 0.5 McFarland
suspension of the test organism and filled with standards or samples (50
l) (2, 20). This assay has a limit of detection of 10.0 g/ml with a CV of
4.5%. For daptomycin, blank ¼-in. disks were placed on a preswabbed
plate of antibiotic medium 2 (Difco, Detroit, MI) and spotted with 10 l
of the standard or sample (CV  12%). Each standard and sample was
tested in duplicate. Plates were incubated for 18 to 24 h at 35°C, at which
time the zone sizes were measured using a protocol reader (Micro-
biology International, Frederick, MD). The half-lives, areas under the
concentration-time curves (AUCs), AUC/MIC ratio, and peak concentra-
tions of the antibiotics were determined by using PK Analyst software
(version 1.10; MicroMath Scientific Software, Salt Lake City, UT). The
AUC was determined by the trapezoidal method.
Resistance. Development of resistance was evaluated at multiple time
points throughout the simulation at 0, 8, 24, 48, 72, 96, and 120 h for
daptomycin and vancomycin. Samples of 100 l from each time point
were plated on MH agar (MHA) and brain heart infusion plates contain-
ing 3 times the MICs of daptomycin and vancomycin to assess the devel-
opment of resistance. Plates were examined for growth after 24 to 48 h of
incubation at 35°C. Since we observed additional drug carryover in the
SEVs for televancin (due to lower MIC values), the SEV samples for tel-
evancin could not be plated directly onto MHA to assess the development
of drug resistance. Therefore, the telavancin population analysis was per-
formed on the initial isolate and the isolate at 120 h to assess any shifts in
the population susceptibility from baseline.
Statistical analysis. Changes in CFU/g at 24, 48, 72, 96, and 120 h were
compared by two-way analysis of variance with Tukey’s post hoc test. A P
value of 0.05 was considered significant. All statistical analyses were
performed using SPSS Inc. (Chicago, IL) statistical software (release
10.07).
RESULTS
MIC results for selected isolates are summarized in Table 1.
CB1814 and SA-684 were confirmed non-hVISA/non-VISA, and
R6212 was determined to be hVISA by modified population anal-
ysis. Observed peak and t1/2 values for vancomycin were 29.2 to
33.7 g/ml (target, 30 g/ml) and 5.2 to 6.5 h (target, 6 h). For
telavancin, achieved peak values were 82.2 to 91.2 g/ml (target,
87.5 g/ml) and achieved t1/2 values were 7.6 to 9.1 h (target, 7.5
h). Daptomycin exhibited peak (target, 95.7 g/ml) and t1/2 (tar-




CB1814 1 4 2
R6212 0.25 2 2
SA-684 0.5 2 2
a TLV, telavancin; DAP, daptomycin; VAN, vancomycin.
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get, 8 h) values of 101.8 to 111.1 g/ml and 7.1 to 9.1 h, respec-
tively.
The quantitative changes in the log10 CFU/g for the tested reg-
imens against the three strains are displayed in Fig. 1A to C. As
shown, telavancin displayed sustained bactericidal activities
against all three strains. Against CB1814, telavancin displayed sus-
tained bactericidal activity (4.9 log10 CFU/g at 120 h) and a
statistically significantly greater reduction in CFU/g at 120 h than
daptomycin or vancomycin (P  0.05). Telavancin also displayed
early (32 h) and sustained bactericidal activity (4.31 log10 CFU/g
at 120 h) against R6212. Against SA-684, telavancin maintained
bactericidal activity at 120 h (3.06 log10 CFU/g). Vancomycin
did not display sustained bactericidal activity against any strain. At
120 h, telavancin reduced the CFU/g significantly more than van-
comycin against R6212 and SA-684 (P  0.05). Daptomycin dis-
played initial bactericidal activity followed by regrowth for all
three strains. No isolates with additional nonsusceptibility to dap-
tomycin or resistance to vancomycin were recovered. Evaluation
of isolates by telavancin population analysis revealed similar pro-
files before and after exposure to telavancin in the SEV in vitro
PK/PD model, with a slight shift for SA-684 (Fig. 2).
DISCUSSION
The optimal treatment for DNS S. aureus infections remains to be
defined, and current treatment options are based on limited evi-
dence (4, 21). Increasing the treatment challenges associated with
these infections, DNS S. aureus is most commonly found in deep-
seated high-inoculum infections, such as osteomyelitis, septic ar-
thritis, and endocarditis, which require long-term treatment (4).
In this study we evaluated the activity of the new lipoglycopeptide
telavancin against DNS S. aureus in an in vitro PK/PD model of
simulated endocardial vegetations. This in vitro model incorpo-
rates a high inoculum of bacteria embedded into human fibrin
and platelets, which are subsequently exposed to antibiotics dosed
to achieve simulation of human pharmacokinetics over the course
of the 5-day evaluation period. Under these experimental condi-
tions, telavancin displayed bactericidal activities against all three
strains tested and was statistically significantly more active than
vancomycin. This additional activity compared to vancomycin is
likely attributable to the dual mechanism of action of telavancin.
Daptomycin displayed activity initially against all strains tested;
however, regrowth occurred due to DNS.
The mechanism by which S. aureus develops nonsusceptibility
to daptomycin is not fully understood; however, it appears to be
due to a series of incremental changes commonly but not univer-
sally found in all DNS S. aureus strains (8, 12, 14, 16, 17, 26,
35–37). In general, DNS S. aureus strains are associated with in-
creased cell surface charge, increased cell wall thickness, changes
in membrane fluidity, and decreased cytoplasmic membrane de-
polarization by daptomycin (11, 25, 26). The increase in positive
cell surface charge is hypothesized to decrease daptomycin activity
via repulsion of the active positively charged daptomycin-Ca2
complex and inhibition of daptomycin-induced membrane per-
turbation (18). Mutations in the mprF gene leading to overexpres-
sion of the MprF protein contribute to increased positive surface
charge via translocation of positively charged phospholipids to the
outer side of the cytoplasmic membrane and by lysinylation of
membrane phosphatidylglycerol (11, 26). Increased D-alanylation
of cell wall teichoic acids via increased expression of the dltABCD
operon also contributes to the increased positive surface charge
(35). An increase in cell wall thickness, which is most commonly
observed in isolates with concurrent decreased susceptibility to
vancomycin, may contribute to DNS via an affinity trapping
mechanism similar to vancomycin in VISA strains (8–10, 36).
Our results demonstrate telavancin’s activity against daptomycin-
nonsusceptible strains of S. aureus. Indeed, the bactericidal activi-
FIG 1 Activity of telavancin, daptomycin, and vancomycin against CB1814
(A), R6212 (B), and SA-684 (C). Telavancin, open triangles; daptomycin, open
squares; vancomycin, open circles; growth control, filled circles; dashed line,
telavancin limit of accuracy.
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ties and decreases in colony counts in this study are similar to
results of a previously published study examining the activity of
telavancin against MRSA, hVISA, and VISA isolates (20). It is
unknown, based on current data, however, if telavancin would
maintain activity against DNS S. aureus isolates that were also
VISA, as these strains were not included in either study.
Possible limitations of this study include its short duration and
lack of strains displaying reduced susceptibility to both vancomy-
cin and daptomycin. It is possible that the study period of 120 h (5
days) was not sufficient to elicit the full impact of a telavancin-
DNS S. aureus interaction that might occur with longer exposures.
As DNS in S. aureus has been associated with reduced susceptibil-
ity to vancomycin, it is likely that the activity telavancin displayed
against DNS S. aureus in this study does not extrapolate to all
strains of DNS S. aureus (24). In conclusion, telavancin displays
bactericidal activity against DNS S. aureus and is more active than
vancomycin. Further research is warranted to explore telavancin’s
activities against these strains.
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